Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
32 Results for "
Nod2
" in MedChemExpress (MCE) Product Catalog:
Products (32)
32 Results for "Nod2" in MCE Product Catalog:
12
12 Publications Verification
Target:
Research Areas:
GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor. GSK717 inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an IC50 of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells .
8
8 Cited Publications
Target:
Research Areas:
NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2, with IC50 of 5.74 μM and 6.45 μM, respectively.
6
6 Cited Publications
Synonyms: MTP-PE; L-MTP-PE; CGP 19835
Target:
Research Areas:
Mifamurtide (MTP-PE), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide has potential for use in rare disease and osteosarcoma research [2] .
6
6 Cited Publications
Synonyms: MTP-PE sodium; L-MTP-PE sodium; CGP 19835 sodium
Target:
Research Areas:
Mifamurtide sodium (MTP-PE sodium), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide sodium is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide sodium has potential for use in rare disease and osteosarcoma research [2] .
6
6 Cited Publications
Cat. No.: HY-13682C
Purity: ≥98.0%
Synonyms: MTP-PE TFA; L-MTP-PE TFA; CGP 19835 TFA
Target:
Research Areas:
Mifamurtide TFA (MTP-PE TFA), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide TFA is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide TFA has potential for use in rare disease and osteosarcoma research [2] .
1
1 Cited Publications
Target:
Research Areas:
PROTAC RIPK degrader-2 is a non-peptidic PROTAC degrader targeting RIPK2, with a DC50 of 1.5 nM. PROTAC RIPK degrader-2 recruits VHL or cereblon E3 ubiquitin ligases, induces ubiquitination and proteasomal degradation of RIPK2, acts via substoichiometric catalysis, and inhibits downstream pro-inflammatory signaling pathways. PROTAC RIPK degrader-2 inhibits the NOD2/RIPK2 pathway and suppresses MDP (HY-127090)-stimulated TNFα release in human whole blood. PROTAC RIPK degrader-2 can be used in studies related to acute monocytic leukemia and glucose metabolism [2].
Research Areas:
NOD2 antagonist 1 is a selective NOD2 antagonist with an IC50 of 5.23 μM. NOD2 antagonist 1 acts directly on the NOD2 protein, downregulates the secretion of pro-inflammatory cytokines such as IL-8 and TNF-α, and inhibits the synergistic cross-response of inflammation mediated by NOD2 and TLR4. NOD2 antagonist 1 can be used in studies related to immunity and inflammation .
Cat. No.: HY-RS09407
Target:
Research Areas:
Nod2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nod2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Target:
Research Areas:
PROTAC RIPK degrader-6 (Example 1) is a RIPK2 PROTAC degrader that recruits cereblon. PROTAC RIPK degrader-6 recruits the CRBN E3 ubiquitin ligase complex and induces the degradation of RIPK2 kinase via the ubiquitin-proteasome pathway, thereby blocking NOD1/NOD2-mediated pro-inflammatory signaling pathways of NF-κB and MAPK. PROTAC RIPK degrader-6 can be used in research related to RIPK2-mediated autoinflammatory diseases and cancer .
Cat. No.: HY-179009
Research Areas:
NOD2 agonist 4 (Compound 12b) is a potent NOD2 agonist with an EC50 of 44.1 nM. NOD2 agonist 4 induces cytokine production (MCP-1, IL-6 and IL-8) in peripheral blood mononuclear cells (PBMCs), both alone and in combination with Lipopolysaccharide (LPS) (HY-D1056). NOD2 agonist 4 can be used for the studies of NOD2-targeted immunomodulator or vaccine adjuvant .
Cat. No.: HY-146034
CAS No.: 2704623-69-6
Target:
Research Areas:
NOD1/2 antagonist-1 (compound 36b) is a potent NOD1/2 (nucleotide-binding
oligomerization domain-like receptor 1/2) dual antagonist, with IC50 values of 1.13 (NOD1) and 0.77 μM (NOD2), respectively. NOD1/2 antagonist-1 has a acceptable T1/2 (67.6 min). NOD1/2 antagonist-1 (compound 36b) can improve the antitumor efficacy of Paclitaxel (PTX) .
Cat. No.: HY-176837
Research Areas:
NOD2/TLR4 agonist-1 (Compound 2) is a NOD2/TLR4 dual agonist. NOD2/TLR4 agonist-1 lacks immunostimulatory activity and serves as an important negative control in research .
Cat. No.: HY-106055
CAS No.: 74817-61-1
Research Areas:
Murabutide is an immunomodulator and also a NOD2 receptor agonist . Murabutide enhances the signal transduction of ATR and NOD2, mediates the activation of the DDR pathway, and thereby repairs radiation-induced DNA double-strand breaks. Murabutide inhibits radiation-induced cell apoptosis and protects cells and mice from radiation-induced toxic damage. Murabutide induces the expression and DNA-binding activity of Oct-1 in macrophages, thereby inhibiting the transcription and replication of HIV-1. Murabutide reduces the expression levels of CD4 and CCR5 on the surface of macrophages, and induces the secretion of β-chemokines, TNF-α and IL-6. Murabutide enhances non-specific viral resistance and targets reticuloendothelial cells. Murabutide can be used in research related to radiation-induced damage and human immunodeficiency virus type 1 infection [2] .
Cat. No.: HY-168158
CAS No.: 2289702-58-3
Target:
Research Areas:
NOD2 agonist 3 (Compound 5) is a potent NOD2 agonist, with an EC50 of 111.45 nM. NOD2 agonist 3 shows immunopotentiating effects .
Cat. No.: HY-168136
CAS No.: 3098609-74-3
Target:
Research Areas:
NOD2 agonist 1 (compund 3) is a potent NOD2 agonist (EC50=4.6 nM) .
Cat. No.: HY-RS09406
Research Areas:
NOD2 Human Pre-designed siRNA Set A contains three designed siRNAs for NOD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS09408
Target:
Research Areas:
Nod2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nod2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-168137
Target:
Research Areas:
NOD2 agonist 2 (compound 23) enhanced the antigen presentation of mouse bone marrow-derived dendritic cells (BMDCs), highlighting its potential as a vaccine adjuvant.
Cat. No.: HY-146694
CAS No.: 2245820-70-4
Research Areas:
RIPK2-IN-1 (compound 18f) is a potent RIPK2 inhibitor with an IC50 of 51 nM. RIPK2-IN-1 inhibits ALK2 with an IC50 of 5 nM. RIPK2-IN-1 has an IC50 of 390 nM on RIPK2/NOD2 in cell assay .
Cat. No.: HY-168024
Target:
Research Areas:
NOD1/2-IN-1 (Compound 18) is a potent RIPK2 inhibitor with an IC50 value of 1.4 nM, as determined by the ADP-Glo assay. NOD1/2-IN-1 blocks the production of pro-inflammatory cytokines by inhibiting the NOD1/NOD2 pathways, with IC50 values of 18 nM and 170 nM for NOD1 and NOD2, respectively, thereby reducing inflammatory responses. NOD1/2-IN-1 can be used in studies related to colitis .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
